EASTERNMED FUNDS VCIC PLC FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

CONTENTS	PAGE
	,
Board of Directors and other officers	1
Fund background	2 - 3
Independent auditors' report	4 - 6
Statement of comprehensive income	7
Statement of financial position	8
Statement of net assets attributable to holders of investor shares	9
Statement of cash flows	10
Notes to the financial statements	11 - 32
Schedule of investments - unaudited	33 - 34

BOARD OF DIRECTORS AND OTHER OFFICERS

Board of Directors:	Athanasios J. Martinos Andreas Theophanous Ioannis Papaioannou Stavros A. Karides Maria Panayi Drakos
Secretary:	K and K Secretarial Limited 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
Management Company:	Easternmed Asset Management Services Ltd 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
Fund Administration:	Fiducitrust Services Limited 66 Acropolis Avenue, Acropolis Tower, 2nd floor 2012 Nicosia Cyprus
External Auditors:	KPMG Limited 14 Esperidon Street 1087 Nicosia Cyprus
External Legal Advisers:	Karides & Karides LLC 11 Kyriakou Matsi Street, Nikis Center, 8th floor 1082 Nicosia Cyprus
Registered office:	48 Themistokli Dervi Avenue Athienitis Centennial Building, Office 104 1066 Nicosia Cyprus
Depositary:	Bank of Cyprus Public Company Ltd 51 Stasinou Street 1398 Nicosia Cyprus
Registration number:	HE354779

FUND BACKGROUND

Introduction

Easternmed Funds VCIC Plc (the "Fund") was incorporated in Cyprus on 19 April 2016 as a public limited liability company under the provisions of the Cyprus Companies Law, Cap. 113. The Fund was granted UCITS license No. UCITS 07/78 by the Cyprus Securities and Exchange Commission on 22 March 2016.

The Fund as an umbrella investment company comprises various sub funds each relating to a separate investment portfolio of securities, cash and other assets. Separate classes of shares are issued in relation to the sub funds. The Board of Directors of the Fund may authorise the creation of additional sub funds/share classes in the future.

As of 31 December 2017, there was 1 sub fund active, Easternmed Equities Fund Class A (the 'Sub Fund') and the Fund's investment activities are managed by Easternmed Asset Management Services Ltd (the 'Management Company'), with the administration delegated to Fiducitrust Services Limited (the 'Fund Administrator').

The prospectus of the Fund has been amended and approved by CySEC as of 28 December 2017. The amended investment policy and investment limits allow the fund manager more flexibility to invest under different market conditions. In addition, the amended investment policy facilitates risk management monitoring, since it includes additional investment limits with exact numerical ranges.

Investment objective

The Fund's objective is to preserve its investors' wealth and to pursue a long-term capital growth strategy subject to moderate volatility with:

- targeted (unlevered) return 3-month Euribor +5% p.a.
- volatility, generally below relevant equity market benchmarks over the investment horizon
- an investment horizon of 10 plus years

Investment strategy

The Fund's investment strategy is characterised as long-term, value-oriented and opportunistic. The Fund invests in highly liquid assets for the long term with emphasis on industries with real rather than intangible assets. While exposures and run comparisons are monitored, there is not at any time strict adherence to commonly used benchmarks. Economic and market risks are closely monitored. In "extreme" market conditions and in order to safeguard the interests of his stakeholders, the investment manager may decide to liquidate the entire portfolio and invest up to 100% of the Fund's assets in cash and/or cash equivalents.

The strategy focuses on portfolio diversification and risk minimisation. Risk is assessed on individual investments as well as on a portfolio level.

The Fund is allowed to borrow on a temporary basis up to 10% of its net assets and may use financial derivatives for hedging purposes.

Investment policy

The Fund invests more than 50% and up to 100% of its Net Asset Value in listed Equities. The Fund invests predominantly in large capitalisation and well-established European companies with a recognisable brand name, solid market share and reputable management. European equity is the main investment. It comprises more than 50% of direct equity investments and up to 100%, while up to 30% is allocated to the US, up to 10% to Emerging Markets and up to 10% to other markets including Japan, Australia, Hong Kong, Singapore, South Korea, Taiwan and Canada.

The Fund's direct equity investments focus predominantly in energy companies up to 35% of the direct equity portfolio; in financials up to 30% of the direct equity portfolio; concerning equities belonging to other market sectors the fund invests up to 20%. Sectors are identified following the GICS taxonomy and includes companies with a solid real asset base in industries such as energy, materials, real estate, hotels, utilities, etc. while investments in companies with high intangible assets (specifically IT patents and brand names but excluding pharmaceutical patents) relative to their asset base, are generally avoided. However, the Fund is also to a limited extent allowed to invest opportunistically in less liquid mid and small-cap equities up to 10% of its direct equity investments.

The Fund further invests a minor portion of its asset (up to 25% of its net assets) in long-only equity funds (UCITS and Other UCIs) with Assets under Management (AuM) in excess of €200 million.

FUND BACKGROUND

The Fund finally invests less than 50% of its net assets in fixed income and cash. Fixed income may include investments in bonds and bond funds (UCITS and Other UCIs), including money market funds, up to 10% of the fund's net assets.

Bonds, qualified as investment grade, represent between 50% and 100% of the bond portfolio. Rating grade criteria are based on the majority of the three main agencies (S&P,Moody's, Fitch). However, the Fund is also allowed to invest, up to 50% of its bond portfolio, in securities belonging to the "speculative grade" i.e., High Yield (HY) and on an exceptional basis (max. 25% within the HY pocket) on non-rated (NR) bonds. Investments in Emerging Market High Yield bonds are limited to instruments for which the Government, including state-owned entities, has an ownership stake of more than 50%.

The Fund predominantly invests on low duration securities (1-3 years' maturities) for higher visibility and as a mean to mitigate credit and interest rate risk. The Fund also invests in "hard currency" debt, predominantly denominated in US Dollars and Euro but the investment manager may also choose to invest in other European currencies such as GBP, NOK, etc. for diversification and/or added yield. Fixed-income securities are deployed as an alternative to cash, preferably with a higher yield. Bonds generally are kept until maturity and are sold only when it is believed that the issuer's creditworthiness is severely undermined by market or company specific events.

The Fund does not invest in ABS, MBS and convertible bonds (or contingent convertible bonds).

Benchmark

The Fund is actively run and the returns or investments of the Fund's portfolio are not compared against a benchmark.



KPMG Limited Chartered Accountants 14 Esperidon Street, 1087 Nicosia, Cyprus P.O. Box 21121, 1502 Nicosia, Cyprus T: +357 22 209000, F: +357 22 678200

1

Independent Auditors' report

TO THE MEMBERS OF EASTERNMED FUNDS VCIC PLC

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Easternmed Funds VCIC Plc (the "Fund") which are presented on pages 7 to 32 and comprise the statement of financial position as at 31 December 2017, and the statements of profit or loss and other comprehensive income, changes in equity and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements give a true and fair view of the financial position of the Fund as at 31 December 2017, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards as adopted by the European Union ("IFRS-EU") and the requirements of the Cyprus Companies Law, Cap. 113, as amended from time to time (the "Companies Law, Cap. 113").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing ("ISAs"). Our responsibilities under those standards are further described in the "Auditors' responsibilities for the audit of the financial statements" section of our report. We are independent of the Fund in accordance with the Code of Ethics for Professional Accountants of the International Ethics Standards Board for Accountants ("IESBA Code"), and the ethical requirements in Cyprus that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

F: +357 25 363842

Paphos P.O. Box 60288, 8101 T: +357 26 943050 F: +357 26 943062

P.O. Box 66014, 8330 T: +357 26 322098 F: +357 26 322722

P.O. Box 50161, 3601 T: +357 25 869000

2.O. Box 40075, 6300 2 +357 24 200000



Responsibilities of the Board of Directors for the financial statements

The Board of Directors is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS-EU and the requirements of the Companies Law, Cap. 113, and for such internal control as the Board of Directors determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Fund's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless there is an intention to either liquidate the Fund or to cease operations, or there is no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Fund's financial reporting process.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Fund to cease to continue as a going concern.



• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves true and fair view.

We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other matter

This report, including the opinion, has been prepared for and only for the Fund's members as a body in accordance with Section 69 of the Auditors' Law of 2017, L.53(I)/2017, as amended from time to time, and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whose knowledge this report may come to.

Maria A. Karantoni, FCA

Ly afant on

Certified Public Accountant and Registered Auditor

for and on behalf of

KPMG Limited

Certified Public Accountants and Registered Auditors 14 Esperidon street 1087 Nicosia Cyprus

23 April 2018

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2017

		Easternmed Equities Fund Class A	Easternmed Equities Fund Class A 19/04/2016 -
	Note	2017 €	31/12/2016 €
Revenue			-
Dividend income	F	1.569.538	55.906
Interest income Net realised gains on financial assets at fair value through profit or loss	5 7	235.693 246.279	118.181 -
Net gains on financial assets at fair value through profit or loss Net foreign currency loss	6,13	2.115.909 (40.822)	1.939.150
Total revenue	•	4.126.597	2.113.237
Management fees		(253.186)	(51.514)
Depositary fees Administration fees		(26.427) (25.301)	(6.104) (6.432)
Directors' fees		(9.570)	(4.846)
Transaction costs Auditors' remuneration		(103.844) (8.449)	(67.006) (4.760)
Legal fees		` - '	` (820)
Secretarial fees Professional fees		(5.772) (44)	(2.850) (1.012)
Incorporation fees		-	(11.000)
Licences and annual contributions Other expenses		(1.800) (654)	(1.402) (5.009)
Total operating expenses	•	(435.047)	(162.755)
Operating profit before finance costs	•	3.691.550	1.950.482
Finance costs	8	(2)	(286)
Increase in net assets attributable to holders of investor shares before tax		3.691.548	1.950.196
Tax	9	(82.668)	(1.511)
Increase in net assets attributable to holders of investor shares for the year/period	:	3.608.880	1.948.685

STATEMENT OF FINANCIAL POSITION AT 31 DECEMBER 2017

	Note	Easternmed Equities Fund Class A 2017 €	Easternmed Equities Fund Class A 2016 €
ASSETS Financial assets at fair value through profit or loss Cash and cash equivalents Other receivables	13 14 12	67.742.900 693.314 180.047	31.371.620 10.354.741
Total assets		68.616.261	41.726.361
LIABILITIES Balances due to brokers Other payables Current tax liabilities	11 16 17	- 56.274 2.422	1.747.327 28.838 1.511
		58.696	1.777.676
Total liabilities (excluding net assets attributable to holders of investor shares)		58.696	1.777.676
Net assets attributable to holders of investor shares		68.557.565	39.948.685
		68.557.565	39.948.685

On 23 April 2018 the Board of Directors of Easternmed Funds VCIC Plc authorised these financial statements for

Athanasios J. Martinos

Director

Ioannis Papaioannou

Director

STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF INVESTOR SHARES FOR THE YEAR ENDED 31 DECEMBER 2017

		Easternmed Equities Fund	Easternmed
		. Class A	. Class A
	Note	2017 €	2016 €
Balance at 1 January/19 April	45	39.948.685	-
Increase in net assets attributable to holders of investor shares	15	3.608.880	1.948.685
Contributions and redemptions by holders of investor shares:			
Subscription for Class A investor shares during the year/period		25.000.000	38.000.000
Total contributions and redemptions by holders of investor shares		25.000.000	38.000.000
Balance at 31 December		68.557.565	39.948.685

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2017

		Easternmed Equities Fund Class A	Easternmed Equities Fund Class A 19/04/2016 -
		2017	31/12/2016
	Note	€	€
CASH FLOWS FROM OPERATING ACTIVITIES			
Increase in net assets attributable to holders of investor shares			
before tax		3.691.548	1.950.196
Adjustments for:	7	(246.270)	
Net realised gains on financial assets at fair value through profit or loss	7 6	(246.279) (2.115.909)	- (1 020 150)
Net gains on financial assets at fair value through profit or loss Net foreign currency loss	O	40.812	(1.939.150)
Dividend income		(1.569.538)	(55.906)
Interest income	5	(235.693)	(118.181)
Changes in working capital:		(435.059)	(163.041)
Increase in other receivables		(180.047)	_
(Increase)/decrease in balances with brokers		(1.747.327)	1.747.327
Increase in other payables		27.436	28.838
	•	(2.334.997)	1.613.124
Cash (used in)/generated from operations Interest received		235.693	118.181
Dividends received		1.569.538	55.906
Proceeds from sale of financial assets at fair value through profit or loss		5.584.686	-
Payments for acquisition of financial assets at fair value through profit or		0.00	
loss		(39.593.778)	(29.432.470)
Tax paid		(81.757)	
Net cash used in operating activities		(34.620.615)	(27.645.259)
. •	•		
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from issue of investor shares	15	25.000.000	38.000.000
Net cash generated from financing activities		25.000.000	38.000.000
Net (decrease)/increase in cash and cash equivalents		(9.620.615)	10.354.741
Cash and cash equivalents at beginning of the year/period		10.354.741	-
Effect of exchange rate fluctuations on cash held		(40.812)	
Cash and cash equivalents at end of the year/period	14	693.314	10.354.741

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

1. Incorporation and principal activities

Country of incorporation

Easternmed Funds VCIC Plc (the "Fund") was incorporated in Cyprus on 19 April 2016 as a public limited liability company under the provisions of the Cyprus Companies Law, Cap. 113. The Fund was granted UCITS license No. UCITS 07/78 by the Cyprus Securities and Exchange Commission on 22 March 2016. Its registered office is at 48 Themistokli Dervi Avenue, Athienitis Centennial Building, Office 104, 1066 Nicosia, Cyprus.

The Fund as an umbrella investment company comprises various sub-funds each relating to a separate investment portfolio of securities, cash and other assets. Separate classes of shares are issued in relation to the sub-funds. The Board of Directors of the Fund may authorise the creation of additional sub-funds/share classes in the future. As of 31 December 2017, there was one sub-fund active, namely the Easternmed Equities Fund Class A (the 'Sub-Fund').

The Fund is primarily involved in investing in a highly diversified portfolio of equity securities issued by companies listed on major European stock exchanges and on the New York Stock Exchange (NYSE), investment funds and corporate debt securities, with the objective of providing shareholders with long-term capital growth subject to moderate volatility.

The Fund's investment activities are managed by Easternmed Asset Management Services Ltd (the 'Management Company'), with the administration delegated to Fiducitrust Services Limited (the 'Fund Administrator').

2. Significant accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented in these financial statements unless otherwise stated.

Basis of preparation

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union (EU) and the requirements of the Cyprus Companies Law, Cap.113. The financial statements have been prepared under the historical cost convention except for financial assets and financial liabilities at fair value through profit or loss.

Adoption of new and revised IFRSs

During the current year the Fund adopted all the new and revised IFRSs as adopted by the EU that are relevant to its operations and are effective for accounting periods beginning on 1 January 2017.

At the date of approval of these financial statements, standards and interpretations were issued by the International Accounting Standards Board which were not yet effective. Some of them were adopted by the EU and others not yet. The Board of Directors expects that the adoption of these accounting standards in future periods will not have a material effect on the financial statements of the Fund.

At the date of approval of these financial statements the following accounting standards were issued by the International Accounting Standards Board but were not yet effective:

(i) Adopted by the European Union New standards

- IFRS 9 "Financial Instruments" (effective for annual periods beginning on or after 1 January 2018).
- IFRS 15 "Revenue from Contracts with Customers" (effective for annual periods beginning on or after 1 January 2018).

Amendments

 Clarifications to IFRS 15 "Revenue from Contracts with Customers" (effective for annual periods beginning on or after 1 January 2018).

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Significant accounting policies (continued)

Adoption of new and revised IFRSs (continued)

(ii) Not adopted by the European Union Amendments

- Annual Improvements to IFRS standards 2015–2017 Cycle (effective for annual periods beginning on or after 1 January 2019).
- Amendments to References to the Conceptual Framework in IFRS Standards (effective for annual periods beginning on or after 1 January 2020).

The Board of Directors expects that the adoption of these standards in future periods will not have a material effect on the financial statements of the Fund.

Revenue recognition

Net fair value gain on financial assets at fair value through profit or loss

Net fair value gain from financial assets at fair value through profit or loss includes all realised and unrealised fair value changes, foreign exchange differences but excludes interest and dividend income.

Interest income

Interest on debt securities at fair value through profit or loss is accrued on a time-proportionate basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition. Interest income is recognised gross of withholding tax, if any. Also, interest income from cash and cash equivalents is recognised on a time-proportionate basis using the effective interest method.

• Dividend income

Dividend income from investments is recognised when the shareholders' rights to receive payment have been established, normally declaration date for final dividends and payment date for interim dividends.

Dividends to holders of investor shares

Dividends to holders of investor shares are recognised in the statement of comprehensive income as finance costs when they are authorised and are no longer at the discretion of the Fund. Dividends are subject to the special defense levy applicable to natural persons, whereas legal entities or natural persons who are not tax residents of Cyprus are exempted from the levy.

Finance costs

Interest expense and other borrowing costs are charged to profit or loss as incurred.

Foreign currency translation

(1) Functional and presentation currency

Items included in the Fund's financial statements are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements are presented in Euro (€), which is the Fund's functional and presentation currency.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Significant accounting policies (continued)

(1) Functional and presentation currency

(2) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary items and non-monetary assets and liabilities that are measured at fair value in a foreign currency are included in profit or loss. Foreign exchange gains and losses on financial assets and financial liabilities at fair value through profit or loss are recognised together with other changes in the fair value. Net foreign exchange gains/(losses) on non-monetary and monetary financial assets and liabilities other than those classified as at fair value through profit or loss are included in the line item net foreign exchange profit in the statement of comprehensive income.

Tax

Current tax liabilities and assets are measured at the amount expected to be paid to or recovered from the taxation authorities, using the tax rates and laws that have been enacted, or substantively enacted, by the reporting date.

Income from investments held by the Fund may be subject to withholding taxes in jurisdictions other than that of the Fund's as imposed by the country of origin. Withholding taxes, if any, are shown in a separate line item in the statement of comprehensive income.

Financial assets

(1) Classification

The Fund classifies its investments in equity and debt securities and open-ended investment funds as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are either held for trading or designated by the Board of Directors at fair value through profit or loss at inception (IAS 39). The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of financial assets at initial recognition.

• Financial assets at fair value through profit or loss

This category has two sub-categories: financial assets held for trading and those designated at fair value through profit or loss at inception. A financial asset is classified as held for trading if acquired principally for the purpose of selling in the short term. Financial assets designated as at fair value through profit or loss at inception are those that are managed and their performance is evaluated on a fair value basis, in accordance with the Fund's documented investment strategy. Information about these financial assets is provided internally on a fair value basis to the Fund's key management personnel. Assets in this category are classified as current assets if they are either held for trading or are expected to be realised within twelve months from the reporting date.

(2) Recognition, derecognition and measurement

Financial assets and liabilities at fair value through profit or loss are recognised when the Fund becomes party to the contractual provisions of the instrument. Recognition takes place on the trade date where the purchase or sale of an investment is under a contract whose terms require delivery of the investment within the time frame established by the market concerned.

Financial assets are derecognised when the contractual rights to the cash flows from the investments have expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities at fair value through profit or loss are derecognised when the obligation specified in the contract is discharged, cancelled or expired. Realised gains and realised losses on derecognition are determined using the weighted average cost method and are included in profit or loss for the period in which they arise.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Significant accounting policies (continued)

Financial assets (continued)

Dividend income from financial assets at fair value through profit or loss is recognised in the statement of comprehensive income within dividend income when the Fund's right to receive payments is established. Interest on debt securities at fair value through profit or loss is recognised in the statement of comprehensive income within interest income based on the effective interest rate. Dividend expense on short sales of equity securities is included within other net changes in fair value on financial assets and financial liabilities at fair value through profit or loss.

At initial recognition financial assets and liabilities are measured at fair value. Transaction costs on financial assets and liabilities at fair value through profit or loss are expensed as incurred in the statement of comprehensive income.

Subsequent to initial recognition, financial assets and liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in their fair value are included in the statement of comprehensive income for the period in which they arise. Interest earned on financial assets at fair value through profit or loss and interest expense on the financial liabilities at fair value through profit or loss are disclosed in a separate line item in the statement of comprehensive income.

Dividend expense on equity securities sold short are included in the net gain or loss arising on financial assets and financial liabilities measured at fair value through profit or loss.

Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short term investments with original maturities of three months or less, bank overdrafts and money market funds with daily liquidity and all highly liquid financial instruments that mature within three months of being purchased.

Amounts due to brokers

Amounts due to brokers are payables for securities purchased (in a regular way transaction) that have been contracted for but not yet settled at the reporting date.

Offsetting financial instruments

Financial assets and financial liabilities are offset and the net amount reported in the statement of financial position if, and only if, there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Income and expenses are presented on a net basis for gains and losses from financial instruments at fair value through profit or loss and foreign exchange gains and losses.

Provisions

Provisions are recognised when the Fund has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made. Where the Fund expects a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain.

Expenses

All expenses are recognised in the statement of comprehensive income on an accrual basis.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Significant accounting policies (continued)

Investor shares and net assets attributable to holders of investor shares

The Fund has two classes of investor shares in issue: Class A and Class B. Both are the most subordinate classes of financial instruments in the Fund and rank pari passu in all material respects and have the same terms and conditions, with the exemption of the subscription, redemption and management fee. As the share classes do not have identical features, these instruments do not meet the definition of puttable financial instruments to be classified as equity in accordance with IAS 32.

Investor shares can be put back into the Fund at any time for cash equal to a proportionate share of the Fund's Net Asset Value ('NAV') attributable to the share class. The investor shares are classified as financial liabilities and are measured at the redemption amounts.

Investor shares are issued and redeemed at the holder's option at prices based on the Fund's net asset value per share at the time of issue or redemption. The Fund's net asset value per share is calculated by dividing the net assets attributable to the holders of each class of investor shares with the total number of outstanding investor shares for each respective class. In accordance with the provisions of the Fund's regulations, investment positions are valued based on the last traded market price for the purpose of determining the net asset value per share for subscriptions and redemptions.

Proposed distributions to holders of investor shares are recognised in the statement of comprehensive income when they are appropriately authorised and no longer at the discretion of the Fund. This typically occurs when proposed distribution is ratified at the Annual General Meeting. The distribution on the investor shares is recognised as a finance cost in the statement of comprehensive income.

Income not distributed is included in net assets attributable to holders of investor shares. Movements in net assets attributable to holders of investor shares are recognised in the statement of comprehensive income as finance costs.

Related party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. Related party transactions are transfers of resources or obligations between related parties, regardless of whether a price is charged.

Events after the reporting period

Assets and liabilities are adjusted for events that occured during the period from the reporting date to the date of approval of the financial statements by the Board of Directors, when these events provide additional information for the valuation of amounts relating to events existing at the reporting date or imply that the going concern concept in relation to part of the whole of the Fund is not appropriate.

Comparatives

Where necessary, comparative figures have been adjusted to conform to changes in presentation in the current year.

3. Financial risk management

Financial risk factors

The Fund is exposed to credit risk, liquidity risk, market risk and operational risk arising from the financial instruments it holds. The risk management policies employed by the Fund to manage these risks are discussed below:

3.1 Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Fund. The Fund is exposed to credit risk from its operating activities, primarily from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

3.1 Credit risk (continued)

At reporting date, the main concentration to which the Fund is exposed arises from the Fund's investments in debt securities. The Fund is also exposed to counterparty credit risk on cash and cash equivalents and other receivable balances. It is the opinion of the Board of Directors that the carrying amounts of these financial assets represent the maximum credit risk exposure at the reporting date.

The Board of Directors has a documented policy in place of spreading the aggregate value of transactions concluded amongst approved counterparties with an appropriate credit quality. The Fund's exposure and the credit ratings of its counterparties are continuously monitored by management. The following table summarises the credit quality of the debt instruments in the portfolio, as rated by well-known rating agencies such as Standard & Poor's approved by the Board of Directors, or in the case of an unrated debt instrument, the rating as assigned by the Board of Directors using an approach consistent with that of the respective rating agencies.

3.1.1 Analysis of credit quality on financial assets

Cash and cash equivalents

The Fund's cash and cash equivalents are held mainly with Bank of Cyprus Public Company Ltd, which is rated Caa2 based on Moody's ratings. The investment manager monitors the financial position of Bank of Cyprus Public Company Ltd on a monthly basis.

Investments in debt securities

At 31 December, the Fund invested in corporate debt securities with the following credit quality. The ratings are based on Standard & Poor's ratings.

	Easternmed Equities	Easternmed Equities	Easternmed Equities	Equities
	Fund Class A	Fund Class A	Fund Class A	Fund Class A
	2017	2016	2017	2016
	€	€	%	%
BBB+	479.188	545.587	16,29%	9,36%
BBB-	154.089	1.157.645	5,24%	19,86%
BB+	845.108	969.252	28,72%	16,62%
BB-	1.041.185	1.039.938	35,39%	17,84%
B+	-	1.092.899	-	18,75%
Unrated	422.598	1.024.630	14,36%	17,57%
Total	2.942.168	5.829.951	100,00%	100,00%

3.1.2 Concentration of credit risk of financial assets

The investment manager reviews the credit concentration of debt securities held based on counterparties and industries.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

3.1 Credit risk (continued)

3.1.1 Concentration of credit risk of financial assets (continued)

As at the reporting date, the Fund's debt securities exposures were concentrated in the following industries.

	Easternmed Equities Fund	Easternmed Equities Fund
	Class A	Class A
	2017	2016
	%	%
Communications	35,39%	18,75%
Consumer Discretionary	16,29%	9,36%
Energy	14,36%	35,41%
Financials	33,96%	27,73%
Materials		8,75%
	100,00%	100,00%

3.2 Liquidity risk

Liquidity risk is the risk that the Fund may not be able to generate sufficient cash resources to settle its obligations in full as they fall due or can only do so on terms that are materially disadvantageous.

The Fund is exposed to the daily settlement of cash redemptions of investor shares. The Fund's investor shares are redeemable at the shareholders' option at any time for cash equal to a proportionate share of the Fund's NAV. The Fund is therefore potentially exposed to redemptions by its shareholders.

The Fund invests primarily in marketable securities and other financial instruments, which under normal market conditions are readily convertible to cash. The Fund's marketable securities and other financial instruments are considered readily realisable, as the majority are listed on the New York and European stock exchanges. Its policy is therefore to invest the majority of its assets in investments that are traded in an active market and can be readily disposed. Only a limited proportion of its assets in investments are not actively traded on a stock exchange. In addition, the Fund's policy is to maintain sufficient cash and cash equivalents to meet normal operating requirements and expected redemption requests.

The Fund's financial assets include investments in unlisted open-ended investment funds which may not be readily realisable due to lock-up periods, extended withdrawal, notice or settlement periods or in extraordinary cases periods in which redemptions are suspended due to adverse market conditions.

It is the Fund's policy that the investment manager and the Board of Directors monitor the Fund's liquidity position on a weekly basis.

The following tables detail the Fund's remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Fund can be required to pay. The table includes both interest and principal cash flows.

31 December 2017	Carrying amounts €	Contractual cash flows €		3-12 months €
Accruals	56.274	56.274	56.274	-
Net assets attributable to holders of investor shares	68.557.565	68.557.565	68.557.565	
	68.613.839	68.613.839	68.613.839	-

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

3.2 Liquidity risk (continued)

31 December 2016	Carrying amounts €	Contractual cash flows €	3 months or less €	3-12 months €
Accruals	27.352	27.352	20.212	7.140
Other creditors	1.076	1.076	1.076	-
Payables to related parties	410	410	410	-
Balances due to brokers	1.747.327	1.747.327	1.747.327	-
Net assets attributable to holders of investor shares	39.948.685	39.948.688	39.948.688	
	41.724.850	41.724.853	41.717.713	7.140

The tables above show the undiscounted cash flows of the Fund's financial liabilities on the basis of their earliest possible contractual maturity. The Fund's expected cash flows on these instruments (other than net assets attributable to the holders of investor shares) do not vary significantly from this analysis. For net assets attributable to the holders of investor shares, the Fund has a contractual obligation to redeem within four working days from the date the application for the redemption of the investor shares is submitted.

3.3 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Fund's income or the value of its holdings of financial instruments.

The Fund's market risk is managed on a monthly basis by the investment manager in accordance with the policies and procedures in place and through diversification of the investment portfolio. The Fund's market positions are monitored on a quarterly basis by the Board of Directors.

3.3.1 Price risk

Price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting similar financial instruments traded in the market.

The Fund is exposed to financial instruments price risk because of investments held by the Fund and classified on the statement of financial position at fair value through profit or loss. The Fund is not exposed to commodity price risk.

The investment manager manages the Fund's price risk on a monthly basis and through diversification of the investment portfolio. The Fund's overall market positions are monitored on a quarterly basis by the Board of Directors.

Sensitivity analysis

A five percent change in prices is the sensitivity rate used when reporting price risk internally to key management personnel and representing management's assessment of a reasonably possible change in prices.

At 31 December 2017, if prices had been five percent higher with all other variables held constant, the increase in net assets attributable to holders of investor shares for the year would have been €3.384.629 higher, arising due to the increase in the fair value of financial assets at fair value through profit or loss by €3.384.629.

If prices had been five percent lower with all other variables held constant the decrease in net assets attributable to holders of investor shares for the year would have been €3.384.629 lower, arising mainly due to the decrease in the fair value of financial assets at fair value through profit or loss by €3.384.629.

3.3.2 Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

3.3. Market risk (continued)

3.3.2 Interest rate risk (continued)

The Fund is exposed to interest rate risk as it invests in listed debt securities bearing interest at both fixed and floating interest rates. Other financial assets exposed to interest rate risk include cash and bank balances which are invested at short term interest rates. The investment manager manages the Fund's exposure to interest rate risk on a monthly basis in accordance with the Fund's investment objectives and policies. The Fund's overall exposure to interest rate risk is monitored on a quarterly basis by the board of directors.

The following table details the Fund's exposure to interest rate risk as at 31 December 2017 by the earlier of contractual maturities or re-pricing:

31 December 2017	Non- interest bearing €	Less than 1 month €	1-3 months €	3 months to 1 year €	More than 1 year €	Total €
Non-interest bearing Floating interest rate debt securities Fixed interest rate debt securities Cash and bank balances	64.800.732 - - -	- - - 693.314	154.089 1.059.571 -	1.316.068 - -	- 412.440 -	64.800.732 154.089 2.788.079 693.314
Total assets	64.800.732	693.314	1.213.660	1.316.068	412.440	68.436.214
Liabilities (excluding net assets attributable to holders of investor shares)						
Non-interest bearing Net assets attributable to holders of	56.274	-	-	-	-	56.274
investor shares	68.557.565	<u> </u>			-	<u>68.557.565</u>
Total liabilities	68.613.839	-		-	-	68.613.839
31 December 2016	Non- interest bearing €	Less than 1 month €	1-3 months €	3 months to 1 year €	More than 1 year €	Total €
31 December 2016 Non-interest bearing Floating interest rate debt securities Fixed interest rate debt securities Cash and bank balances	interest bearing	1 month		to 1 year	1 year	
Non-interest bearing Floating interest rate debt securities Fixed interest rate debt securities	interest bearing €	1 month € 1.043 10.354.741	€ - - 74.566	to 1 year € - - 14.408	1 year € - 154.147 5.585.787	€ 25.541.669 155.190 5.674.761
Non-interest bearing Floating interest rate debt securities Fixed interest rate debt securities Cash and bank balances Total assets Liabilities (excluding net assets attributable to holders of investor shares)	interest bearing € 25.541.669 - - - 25.541.669	1 month € 1.043 10.354.741	€ - 74.566 -	to 1 year € - - 14.408	1 year € - 154.147 5.585.787	€ 25.541.669 155.190 5.674.761 10.354.741 41.726.361
Non-interest bearing Floating interest rate debt securities Fixed interest rate debt securities Cash and bank balances Total assets Liabilities (excluding net assets attributable to holders of investor	interest bearing € 25.541.669	1 month € 1.043 10.354.741	€ - 74.566 -	to 1 year € - - 14.408	1 year € - 154.147 5.585.787	25.541.669 155.190 5.674.761 10.354.741

In accordance with the Fund's policies, the investment manager monitors the Fund's overall interest sensitivity on a monthly basis and the Board of Directors reviews it on a quarterly basis.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

3.3. Market risk (continued)

3.3.3 Currency risk

Currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Fund invests in securities and other investments that are denominated in currencies other than the Euro. Accordingly, the value of the Fund's assets may be affected favorably or unfavorably by fluctuations in currency rates and therefore the Fund is subject to foreign exchange risks. The Fund undertakes certain transactions denominated in foreign currencies and hence is exposed to the effects of exchange rate fluctuations. The Fund's management monitors the exchange rate fluctuations on a continuous basis and acts accordingly.

The carrying amounts of the Fund's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:

		Liabilities		Assets
	Easternmed	Easternmed	Easternmed	Easternmed
	Equities Fund	Equities Fund	Equities Fund	Equities Fund
	Class A	Class A	Class A	Class A
	2017	2016	2017	2016
	€	€	€	€
United States Dollars	-	-	13.252.710	4.083.164
British Pounds	-	-	9.071.526	4.354.960
Swiss Franc	-	-	2.903.264	2.777.867
Swedish Krona	-	-	864.331	884.899
Norwegian Krone	-	852.534	572.104	849.599
Danish Krone			763.811	
		852.534	27.427.746	12.950.489

Sensitivity analysis

A 10% strengthening of the Euro against the following currencies at 31 December 2017 would have increased (decreased) net assets attributable to holders of investor shares by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. For a 10% weakening of the Euro against the relevant currency, there would be an equal and opposite impact on net assets attributable to holders of investor shares.

	Easternmed Equities Fund Class A 2017 €	Net Assets Easternmed Equities Fund Class A 2016 €
United States Dollars British Pounds Swiss Franc Swedish Krona Norwegian Krone Danish Krone	1.325.271 907.153 290.326 86.433 57.210 76.381	408.316 435.496 277.787 88.490 84.960
	2.742.774	1.295.049

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

3.4 Operational risk

Operational risk is the risk of direct or indirect loss arising from a wide variety of causes associated with the processes, technology and infrastructure supporting the Fund's activities with financial instruments, either internally within the Fund or externally at the Fund's service providers, and from external factors other than credit, market and liquidity risks such as those arising from legal and regulatory requirements and generally accepted standards of investment management behaviour.

The Fund's objective is to manage operational risk so as to balance the limiting of financial losses and damage to its reputation with achieving its investment objective of generating returns to investors.

The primary responsibility for the development and implementation of controls over operational risk rests with the Board of Directors. This responsibility is supported by the development of overall standards for the management of operational risk, which encompasses the controls and processes at the service providers and the establishment of service levels with the service providers, in the following areas:

- · documentation of controls and procedures
- requirements for:
 - appropriate segregation of duties between various functions, roles and responsibilities
 - reconciliation and monitoring of transactions
 - periodic assessment of operational risk faced
- the adequacy of controls and procedures to address the risks identifie
- compliance with regulatory and other legal requirements
- · development of contingency plans
- training and professional development
- · ethical and business standards
- risk mitigation, including insurance if this is effective

The directors' assessment of the adequacy of the controls and processes in place at the service providers with respect to operational risk is carried out via regular discussions with the service providers and a review of the service providers' Service Organisation Controls (SOC) 1 reports on internal controls, if any are available.

Substantially all of the assets of the Fund are held by Bank of Cyprus Public Company Ltd (the 'Depositary'). The bankruptcy or insolvency of the Fund's Depositary may cause the Fund's rights with respect to the securities held by the Depositary to be limited. The investment manager monitors the credit ratings and capital adequacy of its Depositary on a monthly basis, and reviews the findings documented in the SOC 1 report on the internal controls annually.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

3.5 Fair value estimation

The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and securities) are based on quoted market prices at the close of trading on the year-end date. The quoted market price used for financial assets and financial liabilities of the Fund is the last traded price provided such price is within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the points within the bid-ask spread that are most representative of the fair value. The price used is not adjusted for transaction costs.

A financial instrument is regarded as quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.

The fair value of financial assets and liabilities that are not traded in an active market is determined by using valuation techniques. The Fund uses a variety of methods and makes assumptions that are based on market conditions existing at each year-end date. Valuation techniques used include the use of comparable recent arm's length transactions, reference to other instruments that are substantially the same, discounted cash flow analysis, option pricing models and other valuation techniques commonly used by market participants, making the maximum use of observable inputs and relying as little as possible on unobservable inputs.

For instruments for which there is no active market, the Fund may also use internally developed models, which are usually based on valuation methods and techniques generally recognised as standard within the industry. Some of the inputs to these models may not be market observable and are therefore estimated based on assumptions.

The output of a model is always an estimate or approximation of a value that cannot be determined with certainty, and valuation techniques employed may not fully reflect all factors relevant to the positions the Fund holds. Valuations are therefore adjusted, where appropriate, to allow for additional factors including model risk, liquidity risk and counterparty risk.

Fair value measurements recognised in statement of financial position

The level of the fair value hierarchy of an instrument is determined considering the inputs that are significant to the entire measurement of such instrument and the level of the fair value hierarchy within which those inputs are categorised.

The fair value hierarchy categorises inputs into the following levels:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity
 can access at the measurement date;
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Fund. The Fund considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

Unobservable inputs are used to measure fair value to the extent that relevant observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. However, the fair value measurement objective remains the same, i.e., an exit price at the measurement date from the perspective of a market participant that holds the asset or owes the liability. Therefore, unobservable inputs reflect the assumptions that market participants would use when pricing the asset or liability, including assumptions about risk.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

The following table provides an analysis of financial instruments measured at fair value at the year end date by the level in the fair value hierarchy into which the fair value measurement is categorised. All these fair value measurements are recurring.

31 December 2017	Level 1 €	Level 2 €	Level 3 €	Total €
Financial assets designated at fair value through profit or loss at inception:				
Equity securities				
Financials	11.882.222	-	-	11.882.222
Materials	11.871.507	-	-	11.871.507
Energy	16.089.368	-	-	16.089.368
Utilities	6.965.638	-	-	6.965.638
Consumer Staples	1.525.175	-	-	1.525.175
Technology	1.556.561	-	-	1.556.561
Industrials	6.576.888	-	-	6.576.888
Health Care	1.971.849	-	-	1.971.849
Communications	1.231.823	-	-	1.231.823
Consumer Discretionary	2.060.400	-		2.060.400
	61.731.431			61.731.431
Listed open-ended investment funds				
Health Care	986.948			986.948
	986.948		-	986.948
Unlisted open-ended investment funds				
Health Care		2.082.353		2.082.353
	_	2.082.353	-	2.082.353
Debt securities				_
Energy	422.598	-	-	422.598
Financials	999.197	-	-	999.197
Communications	1.041.185	-	-	1.041.185
Consumer Discretionary	479.188		<u> </u>	479.188
·	2.942.168	-	-	2.942.168
Total	65.660.547	2.082.353		67.742.900

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

3. Financial risk management (continued)

31 December 2016	Level 1 €	Level 2 €	Level 3 €	Total €
Financial assets designated at fair value through profit or loss at inception:				
Equity securities				
Financials	7.374.228	-	-	7.374.228
Materials	5.045.041	-	-	5.045.041
Energy	3.019.478	-	-	3.019.478
Utilities	1.875.950	-	-	1.875.950
Consumer Staples	1.592.597	-	-	1.592.597
Technology	1.445.949	-	-	1.445.949
Industrials	1.434.629	-	-	1.434.629
Health Care	866.375	-	-	866.375
Communications _	<u>851.832</u>		<u> </u>	851.832
-	23.506.079			23.506.079
Listed open-ended investment funds				
Health Care	969.960	<u> </u>	<u> </u>	969.960
	<u>969.960</u>			969.960
Unlisted open-ended investment funds				
Health Care		1.065.630		1.065.630
		<u> 1.065.630</u>	<u> </u>	1.065.630
Debt securities				
Energy	2.064.568	-	-	2.064.568
Financials	1.616.687	-	-	1.616.687
Communications	1.092.899	-	-	1.092.899
Consumer Discretionary	545.587	-	-	545.587
Materials _	510.210	<u> </u>	<u> </u>	510.210
-	5.829.951			5.829.951
Total _	30.305.990	1.065.630		31.371.620

Valuation techniques and the inputs used for the fair value measurements categorised within Level 2 of the fair value hierarchy is given below:

Unlisted open-ended investment funds

The Fund invests in managed funds, which are not quoted in an active market and which may be subject to restrictions on redemptions such as lock up periods, redemption gates and side pockets. The Fund's investment manager considers the valuation techniques and inputs used in valuing these funds as part of its due diligence prior to investing, to ensure they are reasonable and appropriate and therefore the NAV of these funds may be used as an input into measuring their fair value. In measuring this fair value, the NAV of the funds is adjusted, as necessary, to reflect restrictions on redemptions, and other specific factors of the fund and fund manager. In measuring fair value, consideration is also given to any transactions in the shares of the fund. Depending on the nature and level of adjustments needed to the NAV and the level of trading in the fund, the Fund classifies these funds as either Level 2 or Level 3.

There were no transfers between Level 1 and Level 2 in the year.

4. Critical accounting estimates and judgements

The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates and requires Management to exercise its judgement in the process of applying the Fund's accounting policies. It also requires the use of assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on Management's best knowledge of current events and actions, actual results may ultimately differ from those estimates.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

4. Critical accounting estimates and judgements (continued)

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Income taxes

Significant judgment is required in determining the provision for income taxes. There are transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Company recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the year in which such determination is made.

5. Interest income

	Easternmed Equities Fund Class A	Equities Fund
	Class A	Class A 19/04/2016 -
	2017	31/12/2016
	€	€
Cash and cash equivalents	7.748	978
Listed debt securities designated as at fair value through profit or loss	227.945	117.203
	235.693	118.181

6. Net gain from financial instruments at fair value through profit or loss

Net gain from financial assets designated at fair value through profit or loss is analysed as follows:

	Easternmed Equities Fund	Easternmed
	Class A	Class A
	2017	19/04/2016 - 31/12/2016
	€	€
Equity securities	2.328.999	1.852.259
Listed open-ended investment funds	11.322	(28.305)
Unlisted open-ended investment funds	75.896	4.781
Debt securities	(300.308)	110.415
	2.115.909	1.939.150

The gain from financial instruments at fair value through profit or loss represents the difference between the carrying amount of a financial instrument at the beginning of the reporting period and its carrying amount at the end of the reporting period.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

7. Net realised gains on financial assets at fair value through profit or loss

Net realised gains on financial assets at fair value through profit or loss is analysed as follows:

Eas	sternmed	Easternmed
Equit	ties Fund I	Equities Fund
	Class A	Class A
		19/04/2016 -
	2017	31/12/2016
	€	€
Equity securities	319.892	-
Debt securities	(73.613)	
	246.279	

The realised gains on financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial asset at the beginning of the reporting period, or the transaction price if it was purchased in the current reporting period, and its settlement price.

8. Finance costs

Easternmed Equities Fund	Easternmed Equities Fund
Class A	•
2017 €	31/12/2016 €
Sundry finance expenses	286
2	286

9. Tax

	Easternmed Equities Fund	Easternmed Equities Fund
	Class A	Class A 19/04/2016 -
	2017	31/12/2016
	€	€
Corporation tax - current year/period Withholding tax	5.098 	1.511
Charge for the year/period	82.668	1.511

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

9. Tax (continued)

The tax on the Fund's profit before tax differs from the theoretical amount that would arise using the applicable tax rates as follows:

	Easternmed Equities Fund Class A 2017	Easternmed Equities Fund Class A 19/04/2016 - 31/12/2016
	€	€
Increase in net assets attributable to holders of investor shares before tax	3.691.548	1.950.196
Applicable tax rates	12,50	12,50
Tax calculated at the applicable tax rates	461.444	243.775
Tax effect of expenses not deductible for tax purposes	51.212	12.800
Tax effect of allowances and income not subject to tax	(507.778)	(255.201)
10% additional charge	220	137
Withholding tax	77.570	
Tax charge	82.668	1.511

The corporation tax rate is 12,5%.

Under certain conditions interest income may be subject to defense contribution at the rate of 30%. In such cases this interest will be exempt from corporation tax. In certain cases, dividends received from abroad may be subject to defense contribution at the rate of 17%.

10. Classification and fair values of financial assets and liabilities

The table below provides a reconciliation of the line items in the Fund's statement of financial position to the categories of financial instruments.

31 December 2017	Designated at fair value	Loans and receivables	Total
	€	€	€
Cash and cash equivalents	-	693.314	693.314
Financial assets at fair value through profit or loss	67.742.900		67.742.900
Total	67.742.900	693.314	68.436.214
		Other financial	
		liabilities	Total
		€	€
Net assets attributable to holders of investor shares		68.557.565	68.557.56 <u>5</u>
Total	_	68.557.565	68.557.565

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

10. Financial instruments by category (continued)

Designated at fair value €	Loans and receivables €	Total €
-	10.354.741	10.354.741
31.371.620	<u> </u>	31.371.620
31.371.620	10.354.741	41.726.361
(Other financial	
	liabilities	Total
	€	€
	1.747.327	1.747.327
	1.747.327 1.486	1.747.327 1.486
	value € - 31.371.620 31.371.620	value € receivables € - 10.354.741 31.371.620 - 31.371.620 10.354.741 Other financial liabilities

11. Balances due to brokers

	Easternmed Equities Fund Class A 2017 €	Equities Fund
Balances due to brokers Purchases awaiting settlement	_	1.747.327
	<u>.</u>	1.747.327

During 2016, two acquisitions of equity securities took place which were not settled prior to the year end. Both acquisitions were settled in January 2017.

The exposure of the Fund to liquidity risk in relation to balances due to brokers is reported in note 3 of the financial statements.

12. Other receivables

	Easternmed Equities Fund	Easternmed Equities Fund
	. Class A	. Class A
	2017	2016
	€	€
Other receivables	180.047	
	180.047	

Other receivables include final dividends for equity securities in financial assets at fair value through profit or loss, which were declared during the year with a pay date in 2018. The outstanding declared dividends for the year ended 31 December 2017 totaled €180.047 (2016: Nil) and are presented in the statement of financial position in other receivables.

The exposure of the Fund to credit risk and impairment losses in relation to trade and other receivables is reported in note 3 of the financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

13. Financial assets at fair value through profit or loss

	Easternmed Equities Fund	Easternmed Equities Fund
	Class A 2017	Class A 2016
	€	2010
Balance at 1 January/19 April	31.371.620	-
Additions	39.593.778	29.432.470
Disposals	(5.338.407)	-
Net gains from change in value	2.115.909	1.939.150
Balance at 31 December	67.742.900	31.371.620

Financial assets designated as at fair value through profit or loss are analysed as follows:

	Easternmed Equities Fund Class A 2017 €	
Financial assets at fair value through profit or loss		
Equity securities	61.731.431	23.506.079
Listed open-ended investment funds	986.948	969.960
Unlisted open-ended investment funds	2.082.353	1.065.630
Debt securities	2.942.168	5.829.951
	67.742.900	31.371.620

The financial assets at fair value through profit or loss are marketable securities and are valued at market value at the close of business on 31 December by reference to Stock Exchange quoted bid prices or over the counter prices. The fair value estimation of the financial assets at fair value through profit or loss is disclosed in note 3.

In the statement of cash flows, financial assets at fair value through profit or loss are presented within the section on operating activities as part of changes in working capital. In the statement of comprehensive income, changes in fair values of financial assets at fair value through profit or loss are recorded in operating income.

The exposure of the Fund to market risk in relation to financial assets is reported in note 3 of the financial statements.

14. Cash and cash equivalents

For the purposes of the statement of cash flows, the cash and cash equivalents include the following:

		Easternmed Equities Fund
	Class A 2017 €	Class A 2016
Cash at bank	693.314	10.354.741
	693.314	10.354.741

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

14. Cash and cash equivalents (continued)

Cash and cash equivalents by currency:

	Easternmed	Easternmed
	Equities Fund I	Equities Fund
	Class A	Class A
	2017	2016
	€	€
United States Dollars	5.830	55.311
Euro	665.378	9.425.373
British Pounds	22.012	23.756
Norwegian Krone	94	850.301
	693.314	10.354.741

The exposure of the Fund to credit risk and impairment losses in relation to cash and cash equivalents is reported in note 3 of the financial statements.

15. Net assets attributable to holders of investor shares

Investor shares

The Fund was set up with authorised share capital of 500.000.000 investor shares, no fractions of a share are recognised and each share represents the same percentage holding in the overall assets. The price of each investor share in the Fund, at the time of incorporation, was set at €100, with euro as reference currency.

The initial issued share capital of the Fund is 2.000 investor shares issued at the price of €100 each.

Investor shares are classified into Class A investor shares and Class B investor shares. The rights and obligations of the two share classes are identical, with the exemption of the subscription, redemption and management fee charge.

The Minimum Holding and Minimum Initial Subscription required for Class A investor shares is €800.000 and the Minimum Additional Subscription required for Class A investor shares is €500.000. The Minimum Holding, Minimum Initial Subscription and Minimum Additional Subscription required for Class B investor shares is €5.000. These minimum initial and additional subscription amounts may be reduced or increased, at the discretion of the Fund, whenever the Fund considers it reasonable or appropriate, taking into consideration the diversification of shareholders and other factors and subject to the provisions for amendment to the instruments of incorporation of the Fund.

	Easternmed Equities Fund Class A 2017 Number of shares	Easternmed Equities Fund Class A 2017	Easternmed Equities Fund Class A 2016 Number of shares	Easternmed Equities Fund Class A 2016
Issued and fully paid Balance at 1 January/19 April Increase in net assets attributable to holders of	359.442	39.948.685	-	-
investor shares Issue of investor shares during the year/period	- 215.462	3.608.880 25.000.000	- 359.442	1.948.685 38.000.000
Balance at 31 December	574.904	68.557.565	359.442	39.948.685

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

15. Net assets attributable to holders of investor shares (continued)

The rights attaching to the investor shares are as follows:

- The shares may be redeemed daily at the net asset value per share of the respective class.
- The shares carry a right to receive notice of, attend and vote at general meetings.
- The holders of investor shares are entitled to receive all dividends declared and paid by the Fund. On windingup, the holders are entitled to a return of capital based on the net asset value per share of their respective classes and if applicable to the class the subscription, and redemption fee.

16. Other payables

	Easternmed	Easternmed
	Equities Fund	Equities Fund
	Class A	Class A
	2017	2016
	€	€
Accruals	56.274	27.352
Other creditors	-	1.076
Payables to related companies (Note 18.3)		410
	56.274	28.838

The exposure of the Fund to liquidity risk in relation to financial instruments is reported in note 3 of the financial statements.

17. Current tax liabilities

Easternmed	Easternmed
Equities Fund	Equities Fund
Class A	Class A
2017	2016
€	€
Corporation tax 2.422	1.511
2.422	1.511

18. Related party balances and transactions

The related party balances and transactions are as follows:

18.1 Investment manager

The Fund has appointed a Management Company to provide management services pursuant to a management agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the investment manager 0,50% per annum for Class A investor shares and 1% per annum for Class B investor shares of the average net asset value of the Fund for the relevant fiscal year, for managing the Fund. The management fee is computed daily on the daily value of the Fund's net assets and is paid by debiting it from the Fund at the end of each month. The management fee includes fees to enable the Management Company to perform its tasks and functions, or to provide services, irrespective of whether those functions is carried out by the Management Company itself or have been outsourced to third parties.

Management fees for the year ended 31 December 2017 totaled €253.186 (2016: €51.514) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €28.873 (2016: €12.233) and it is included in accruals in other payables.

At 31 December 2017, 10.000 Class A investor shares were held by the investment manager.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

18. Related party balances and transactions (continued)

18.2 Directors' remuneration

Directors' fees paid during the year ended 31 December 2017 totaled €9.570 (2016: €4.846) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €2.393 (2016: €2.143) and it is included in accruals in other payables. Directors' remuneration consisted of only fixed directors' fees and no other staff costs are paid by the Fund.

18.3 Payables to related parties (Note 16)

		Easternmed	Easternmed
		Equities Fund	Equities Fund
		Class A	Class A
		2017	2016
<u>Name</u>	Nature of transactions	€	€
Easternmed Asset Management Services Ltd	Other	<u> </u>	410
		<u> </u>	410

The payables to related parties were provided interest free, and there was no specified repayment date.

19. Other key contracts

The Fund has appointed the Administrator to provide administrative services pursuant to an administration agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the administrative agent 0,05% per annum of the average net asset value of the Fund for the relevant fiscal year, with a floor of €12.500 and a ceiling of €50.000 per annum. The administration fee is computed daily on the daily value of the Fund's net assets and is billed at the end of each month. The administration fees for the year ended 31 December 2017 totaled €25.301 (2016: €6.432) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €2.887 (2016: €1.223) and it is included in accruals in other payables.

The Fund has appointed the Depositary to provide depositary services pursuant to a depositary agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the depositary 0,05% per annum of the average net value of the Fund's assets held by the Depositary during the relevant fiscal year with a minimum fee of €2.500 per quarter. The Depositary's fee is computed daily on the daily valuation of the net assets held by the Depositary and billed at the end of each quarter. This fee includes Depositary fees which may be payable to third parties who undertake to safeguard all or part of the assets of the Fund on the basis of outsourcing arrangements. The depositary fees for the year ended 31 December 2017 totaled €26.427 (2016: €6.104) and are presented in the statement of comprehensive income. The amount outstanding at the year end is €8.641 (2016: €3.211) and it is included in accruals in other payables.

20. Contingent liabilities

The Fund had no contingent liabilities as at 31 December 2017.

21. Commitments

The Fund had no capital or other commitments as at 31 December 2017.

22. Events after the reporting period

There were no material events after the reporting period, which have a bearing on the understanding of the financial statements.

SCHEDULE OF INVESTMENTS - UNAUDITED FOR THE YEAR ENDED 31 DECEMBER 2017

Easternmed	Easternmed
Equities Fund	Equities Fund
Class A	Class A
Percentage of	
net assets	Fair value
2017	2017
%	€

ASSETS

Equity securities, listed		
NYSE and European exchange-traded equity securities:		
120.000 shares in Prudential Plc	2.577.235	3,76%
80.000 shares in LafargeHolcim Ltd	3.763.200	5,49%
96.200 shares in Veolia Environment SA	2.046.655	2,99%
113.807 shares in Suez SA	1.668.980	2,43%
82.000 shares in Axa SA	2.028.270	2,96%
113.852 shares in Total SA	5.242.315	7,65%
30.000 shares in Rio Tinto Plc	1.332.912	1,94%
170.000 shares in BHP Billiton Plc	2.917.225	4,26%
158.000 shares in Telefonaktiebolaget LM Ericsson	864.331	1,26%
200.000 shares in Royal Dutch Shell Plc	5.557.000	8,11%
100.000 shares in Tsakos Energy Navigation Ltd	326.023	0,48%
100.000 shares in ING Groep NV	1.532.500	2,24%
7.000 shares in Capgemini SA	692.230	1,01%
60.000 shares in UBS Group AG	919.843	1,34%
15.000 shares in Nestle SA	1.074.175	1,57%
25.000 shares in Carrefour SA	451.000	0,66%
55.000 shares in Royal Boskalis Westminster NV	1.728.650	2,52%
5.000 shares in Muenchener Rueckversicherungs-Gesellschaft AG	903.750	1,32%
130,000 shares in Iberdrola SA	839.800	1,22%
40.000 shares in Pfizer Inc	1.208.038	1,76%
10.000 shares in BASF SE	917.400	1,34%
22.500 shares in Exxon Mobil Corp	1.569.165	2,29%
15.000 shares in Siemens AG	1.742.250	2,54%
80.000 shares in Gaslog Ltd	1.484.199	2,16%
100.000 shares in Safe Bulkers Inc	269.324	0,39%
10.000 shares in Koninklijke Vopak NV	365.700	0,53%
5.000 shares in Chevron Corp	521.929	0,76%
100.000 shares in Aviva Plc	570.878	0,83%
115.000 shares in E.ON SE	1.042.015	1,52%
52.500 shares in Engie SA	752.588	1,10%
120.000 shares in Engle SpA	615.600	0,90%
30.000 shares in Schlumberger Ltd	1.685.733	2,46%
1.000.000 shares in Lloyds Banking Group PLC	767.107	1,12%
8.000 shares in VP Bank AG	909.246	1,33%
40.710 shares in Cie de Saint-Gobain	1.871.846	2,73%
120.000 shares in TUI AG	2.060.400	3,01%
17.000 shares in Novo Nordisk A/S	763.811	1,11%
85.100 shares in Orange SA	1.231.823	1,80%
11.000 shares in BNP Paribas SA	684.750	1,00%
10.000 shares in BNP Baker Hughes a GE Co	263.821	0,38%
18.000 shares in DowDuPont Inc	1.068.924	1,56%
20.000 shares in Arconic Inc	454.432	0,66%
20.000 shares in Bank of America Corp	492.287	0,72%
8.000 shares in Citigroup Inc	496.356	0,72%
150.000 shares in BP Plc	883.705	1,29%
95.000 shares in Wallenius Wilhelmsen Logistics	572.010	0,83%
Total equity securities, listed	61.731.431	90,04%

SCHEDULE OF INVESTMENTS - UNAUDITED FOR THE YEAR ENDED 31 DECEMBER 2017

FOR THE TEAR ENDED 31 DECEMBER 2017	Easternmed Equities Fund Class A Fair value 2017 €	Easternmed Equities Fund Class A Percentage of net assets 2017 %
Open-ended investment funds, listed European exchange-traded open-ended investment funds: 13.700 units iShares STOXX Europe 600 Health Care UCITS ETF (DE) Total open-ended investment funds, listed	<u>986.948</u> 986.948	<u>1,44%</u> 1,44%
Open-ended investment funds, unlisted Unlisted open-ended investment funds: 58.500 units BlackRock Global Funds - World Healthscience Fund D2 Total open-ended investment funds, unlisted	2.082.353 2.082.353	3,04% 3,04%
Debt securities NYSE, Asia and European exchange-traded debt securities: OTE Plc 7,875% 07/02/2018 Commerzbank AG 2,671% 30/03/2018 Hellenic Petroleum Finance Plc 5,25% 04/07/2019 Volkswagen International Finance NV 2,125% 20/11/2018 Bank of India London 3,625% 21/9/2018 Total debt securities	1.041.185 154.089 422.598 479.188 845.108 2.942.168	1,52% 0,22% 0,62% 0,70% 1,23% 4,29%
Total investments Cash and cash equivalents Other assets in excess of other liabilities and equity Total net assets	67.742.900 693.314 121.351 68.557.565	98,81% 1,01% 0,18% 100,00%